NYSEAMERICAN:IGC IGC Pharma (IGC) Stock Price, News & Analysis → Proof that the Musk/Bezos rivalry is about to hit a new level (From InvestorPlace) (Ad) Free IGC Stock Alerts $0.52 -0.02 (-3.70%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$0.52▼$0.5550-Day Range N/A52-Week Range$0.25▼$0.91Volume230,334 shsAverage Volume792,213 shsMarket Capitalization$34.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesOwnershipSEC FilingsShort Interest Get IGC Pharma alerts: Email Address Ad InvestorPlaceProof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…Go here now for full story. About IGC Pharma Stock (NYSEAMERICAN:IGC)IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Read More IGC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IGC Stock News HeadlinesMay 9, 2024 | stockhouse.com6.7 Million Americans Live With Alzheimer's - IGC Pharma Believes They Deserve Treatment Options Without Black Box WarningsMay 6, 2024 | americanbankingnews.comIGC Pharma (NYSEAMERICAN:IGC) Receives New Coverage from Analysts at StockNews.comMay 9, 2024 | InvestorPlace (Ad)Proof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…April 30, 2024 | americanbankingnews.comStockNews.com Begins Coverage on IGC Pharma (NYSEAMERICAN:IGC)April 17, 2024 | msn.comCDC investigating reports of counterfeit or mishandled Botox injections in 9 statesApril 16, 2024 | benzinga.comIGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated AgitationApril 16, 2024 | stockhouse.comIGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week TwoApril 16, 2024 | finance.yahoo.comIGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week TwoMay 9, 2024 | InvestorPlace (Ad)Proof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…April 9, 2024 | barrons.comIGC Pharma Inc.April 9, 2024 | businesswire.comIGC Pharma Adds Advisor in Artificial IntelligenceApril 2, 2024 | benzinga.comIGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's ResearchMarch 28, 2024 | msn.comAll About Kyle Richards' Mom Kathleen RichardsMarch 26, 2024 | businesswire.comIGC Pharma Announces $3 Million Unregistered Private Placement of its Common StockMarch 20, 2024 | msn.comAlzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To PlaceboMarch 20, 2024 | msn.comEXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early SuccessMarch 20, 2024 | finance.yahoo.comIGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s AgitationMarch 20, 2024 | businesswire.comIGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's AgitationMarch 20, 2024 | businesswire.comIGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024March 12, 2024 | finance.yahoo.comIGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s PipelineMarch 12, 2024 | businesswire.comIGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's PipelineFebruary 28, 2024 | marketwatch.comIGC Pharma Sees Positive Memory Function Data in Preclinical Study of Alzheimer's Disease DrugFebruary 28, 2024 | finance.yahoo.comPromising Results: TGR-63 Enhances Memory in Alzheimer's Mouse ModelFebruary 23, 2024 | finance.yahoo.comIGC Pharma Announces Equity Analyst Coverage by Ascendiant with a "Buy" Recommendation and $3.00 Price TargetFebruary 23, 2024 | businesswire.comIGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price TargetFebruary 19, 2024 | benzinga.comIGC Pharma Stock (AMEX:IGC) Dividends: History, Yield and DatesFebruary 19, 2024 | benzinga.comIGC Pharma Announces Q3 2024 Earnings: Strategic Patent Achievements Propel Forward Amid LossesSee More Headlines Receive IGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today5/09/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:IGC CUSIPN/A CIK1326205 Webwww.igcinc.us Phone(301) 983-0998Fax240-465-0273Employees61Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,510,000.00 Net Margins-1,163.24% Pretax Margin-1,163.24% Return on Equity-110.37% Return on Assets-93.34% Debt Debt-to-Equity Ratio0.02 Current Ratio1.85 Quick Ratio0.86 Sales & Book Value Annual Sales$910,000.00 Price / Sales38.18 Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book1.86Miscellaneous Outstanding Shares66,810,000Free Float54,119,000Market Cap$34.74 million OptionableNot Optionable Beta1.63 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Ram Mukunda (Age 65)President, CEO & Director Comp: $705kMs. Claudia Grimaldi (Age 53)VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director Comp: $245kMr. Rohit Goel (Age 30)Senior Director of Accounting & Principal Accounting Officer Key CompetitorsBriaCell TherapeuticsNASDAQ:BCTXFortress BiotechNASDAQ:FBIOMarker TherapeuticsNASDAQ:MRKRPalatin TechnologiesNYSEAMERICAN:PTNApollomicsNASDAQ:APLMView All Competitors IGC Stock Analysis - Frequently Asked Questions How have IGC shares performed in 2024? IGC Pharma's stock was trading at $0.3446 at the beginning of 2024. Since then, IGC stock has increased by 50.9% and is now trading at $0.52. View the best growth stocks for 2024 here. Are investors shorting IGC Pharma? IGC Pharma saw a decrease in short interest in April. As of April 15th, there was short interest totaling 768,100 shares, a decrease of 18.2% from the March 31st total of 938,800 shares. Based on an average daily trading volume, of 945,700 shares, the short-interest ratio is currently 0.8 days. View IGC Pharma's Short Interest. How were IGC Pharma's earnings last quarter? IGC Pharma, Inc. (NYSEAMERICAN:IGC) released its earnings results on Wednesday, February, 14th. The construction company reported ($0.09) EPS for the quarter. The construction company earned $0.20 million during the quarter. IGC Pharma had a negative trailing twelve-month return on equity of 110.37% and a negative net margin of 1,163.24%. What other stocks do shareholders of IGC Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other IGC Pharma investors own include GW Pharmaceuticals (GWPH), Alibaba Group (BABA), Tilray (TLRY), Cronos Group (CRON), Micron Technology (MU), NewAge (NBEV), Advanced Micro Devices (AMD), Ford Motor (F) and NIO (NIO). How do I buy shares of IGC Pharma? Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:IGC) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersProof that the Musk/Bezos rivalry is about to hit a new levelInvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDems have chosen Biden replacement?Paradigm PressUrgent Nvidia WarningAltimetryTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGC Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.